CF
PTHS

Cantor Fitzgerald’s Pelthos Therapeutics PTHS Stock Holding History

Cantor Fitzgerald’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Sell
38,123
-3,300
-8% -$84.7K 0.01% 229
2026
Q1 		$870K Buy
41,423
+6,433
+18% +$153K 0.01% 184
2025
Q4 		$1.08M Buy
+34,990
New +$1.01M 0.02% 158

Other funds holding PTHS

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Cantor Fitzgerald's PTHS Position: Q2 2026 in Review

Cantor Fitzgerald reduced its Pelthos Therapeutics (PTHS) stake by 8% in Q2 2026, selling an estimated $84.7K and leaving 38,123 shares worth $1.08M. The position accounts for 0.01% of the portfolio, ranked #229.

Cantor Fitzgerald first reported a position in PTHS in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.08M in Q4 2025. 24 funds tracked by Wall St. Rank hold PTHS as of Q2 2026.

  • Cantor Fitzgerald held 38,123 shares of Pelthos Therapeutics worth $1.08M as of Q2 2026.
  • Cantor Fitzgerald sold 3,300 Pelthos Therapeutics shares in Q2 2026, an estimated $84.7K.
  • Pelthos Therapeutics made up 0.01% of Cantor Fitzgerald's portfolio in Q2 2026, its #229 holding.
  • Cantor Fitzgerald first reported a position in Pelthos Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Cantor Fitzgerald's Pelthos Therapeutics position peaked at $1.08M in Q4 2025.
  • 24 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q2 2026.

Based on Cantor Fitzgerald's 13F filing for Q2 2026, filed 14 Aug 2026.